空气中的悬浮颗粒物（PM）是全球主要的健康危害因素，同时也是肺癌的关键因素，肺癌仍然是最常见的恶性肿瘤和导致癌症相关死亡的主要原因。DNA甲基化是PM有害影响的关键机制，然而PM暴露与肺癌之间的分子联系仍有待阐明。N-α-乙酰转移酶10（NAA10）参与细胞周期、迁移、凋亡、分化和增殖。为了研究NAA10在PM诱导导致肺癌的病理生理过程中的作用，我们测定了正常人支气管上皮细胞（NHBE）在受到PM10、PM10-多环芳烃（PAH）和PM2.5处理后NAA10的表达和甲基化，并评估了NAA10甲基化状态在肺癌患者中的预后价值。与模拟处理对照组相比，接触所有PM类型显著增加了NHBE细胞中NAA10 mRNA的表达，并降低了NAA10启动子的甲基化。在140个肺癌组织样本中，9.3％（13/140）表现出NAA10低甲基化，并与NAA10转录上调相关。单变量和多变量分析表明，NAA10低甲基化与肺癌患者生存期缩短相关。因此，这些结果提示，PM诱导的NAA10低甲基化可能在肺癌发病机制中发挥重要作用，并可作为肺癌进展的潜在预后生物标志物。进一步进行大量患者研究以确认我们的发现是必要的。© 2023作者。由Informa UK Limited发布，交易名为Taylor & Francis Group。

Airborne particulate matter (PM) is a major health hazard worldwide and is a key factor in lung cancer, which remains the most common type of malignancy and the leading cause of cancer-related deaths. DNA methylation is a critical mechanism underlying the detrimental effects of PM, however, the molecular link between PM exposure and lung cancer remains to be elucidated. N-α-acetyltransferase 10 (NAA10) is involved in the cell cycle, migration, apoptosis, differentiation, and proliferation. In order to investigate the role of NAA10 in PM-induced pathogenesis processes leading to lung cancer, we determined the expression and methylation of NAA10 in normal human bronchial epithelial (NHBE) cells treated with PM10, PM10-polycyclic aromatic hydrocarbons (PAH), and PM2.5 and evaluated the prognostic value of the NAA10 methylation status in lung cancer patients. Exposure to all PM types significantly increased the expression of NAA10 mRNA and decreased the methylation of the NAA10 promoter in NHBE cells compared with the mock-treated control. NAA10 hypomethylation was observed in 9.3% (13/140) of lung cancer tissue samples and correlated with NAA10 transcriptional upregulation. Univariate and multivariate analyses revealed that NAA10 hypomethylation was associated with decreased survival of patients with lung cancer. Therefore, these results suggest that PM-induced hypomethylation of the NAA10 may play an important role in the pathogenesis of lung cancer and may be used as a potential prognostic biomarker for lung cancer progression. Further studies with large numbers of patients are warranted to confirm our findings.© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.